CVRX Earnings

CVRX reported its earnings on 2026-02-12, showcasing a revenue of 16.02M against an estimate of 15.50M, resulting in a 3.38% surprise. The EPS was -0.46, surpassing the expected -0.42 by -9.52%. The stock experienced a -13.01% price change on the earnings day and a -7.21% change over the next five days, reflecting market reactions to the results.

Following CVRX's earnings announcement on 2026-02-12, the stock price moved by -13.01% on the day of the release. Over the subsequent five days, it saw a -7.21% change. Historically, CVRX's stock price tends to shift by an average of 1.02% in the 10 days leading up to earnings and 0.39% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate CVRX's annual revenue to reach 14.38M, while the EPS is projected at -0.50. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between CVRX's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, CVRX's stock price typically moves by 1.02% in the 10 days before its earnings and 0.39% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -0.50 and revenue of 14.38M.

The earnings call highlights several positive factors: improved revenue and gross margin guidance, the transition to a Category I CPT code, and strong confidence in future growth driven by sales rep productivity and center adoption. The Q&A section supports these positives, with management addressing concerns and outlining strategic initiatives. Despite some vague responses, the overall sentiment is optimistic, with potential catalysts like the FDA IDE application and the BENEFIT trial. The market is likely to react positively, predicting a 2% to 8% increase in stock price.